The Effective Blood Concentration of Ciprofol
Median Effective Concentration of Ciprofol and Its Correlation With Bispectral Index: A Prospective Observational Study
Peking University Shenzhen Hospital
101 participants
Jul 1, 2025
OBSERVATIONAL
Conditions
Summary
1. Eligible patients were selected and enrolled in the study. 2. General anesthesia was induced using ciprofol in all participants, with standardized evaluation of consciousness levels during induction. 3. The patients' pain and cognition are followed up after surgery.
Eligibility
Inclusion Criteria4
- Patients aged 18-65 years
- Scheduled for elective thyroidectomy
- ASA physical status classification I-II
- Willing to participate and providing written informed consent
Exclusion Criteria6
- Recent use of sedatives or opioid analgesics
- Severe hepatic or renal dysfunction defined as:Child-Pugh class C (score ≥10), Creatinine clearance \<35 mL/min ,Requiring preoperative dialysis
- Significant cardiovascular comorbidities
- Body mass index ≥35 kg/m² or \<18.5 kg/m²
- Known hypersensitivity or adverse reactions to propofol/ciprofol
- Neuropsychiatric disorders including:Alzheimer's disease,History of cerebrovascular events,Traumatic brain injury,Space-occupying brain lesions,Other significant neurological deficits
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Beginning with an initial target plasma concentration of ciprofol at 1.2 μg/mL. Assessments of the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scale and Bispectral Index (BIS) values are performed every minute until the patient achieves a complete anesthetic state (defined as an MOAA/S score of 0).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07294989